NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03160885,Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2),https://clinicaltrials.gov/study/NCT03160885,ECZTRA 2,COMPLETED,"Primary objective:

To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).

Secondary objectives:

To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo.

Maintenance objective:

To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.",YES,Atopic Dermatitis,DRUG: Tralokinumab|DRUG: Placebo,"Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16., The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)., At Week 16|Subjects Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI]., The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16","Reduction of Worst Daily Pruritus Numeric Rating Scale (Weekly Average) of at Least 4 From Baseline to Week 16., Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'., Week 0 to Week 16|Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16., The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease., Week 0 to Week 16|Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16., The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their quality of life (QoL) over the last week such as dermatology-related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL., Week 0 to Week 16|Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 52 Among Subjects With IGA of 0/1 at Week 16, The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD and is based on a 5-point scale ranging from 0 (clear) to 4 (severe)., At Week 52|Subjects With at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 52 Among Subjects With EASI75 at Week 16, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 52|Safety and Tolerability: Adverse Event (AE) /Serious Adverse Event (SAE) Frequency, Overall summary of AEs and SAEs during the Initial treatment period is presented. For list of AEs and SAEs by MedDRA system organ class (SOC) and preferred term (PT) during the entire trial period (including safety follow-up), see Adverse Events Overview section., Week 0 to Week 16|Frequency of Anti-drug Antibodies, Anti-tralokinumab antibody levels were analysed using a validated bioanalytical method, Week 0 to Week 16|Subjects Achieving at Least 50% Reduction in Eczema Area and Severity Index [EASI] at Week 16, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16|Subjects Achieving at Least 90% Reduction in Eczema Area and Severity Index [EASI] at Week 16., The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16|Change From Baseline to Week 16 in Eczema Area and Severity Index [EASI] Score, The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe and/or more extensive condition., At Week 16|Subjects Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16., The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease., At Week 16|Subjects Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16., The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease., At Week 16|Change From Baseline to Week 16 in Worst Daily Pruritus NRS (Weekly Average)., Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable', Baseline to Week 16|Reduction of Worst Daily Pruritus NRS (Weekly Average) ≥3 From Baseline to Week 16., Subjects will assess their worst itch severity over the past 24 hours using an 11 point NRS ('Worst Daily Pruritus NRS') with 0 indicating 'no itch' and 10 indicating 'worst itch imaginable'., Baseline to Week 16|Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of ≥4 Points Among Subjects With Baseline DLQI ≥4., The DLQI is a validated questionnaire with content specific to those with dermatology conditions. It consists of 10 items addressing the subject's perception of the impact of their skin disease on different aspects of their QoL over the last week such as dermatology related symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the treatment. Each item is scored on a 4 point Likert scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; 3 = very much). The total score is the sum of the 10 items (0 to 30); a high score is indicative of a poor QoL., Baseline to Week 16",,LEO Pharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,794,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",LP0162-1326|2016-004201-13,2017-06-12,2018-09-04,2019-08-14,2017-05-19,2020-08-07,2023-02-24,"Burke Pharmaceutical Research, Hot Springs, Arkansas, 71913, United States|California dermatology, Encinitas, California, 92024, United States|Advanced SkinCare Surgery & Med Center, Fullerton, California, 92835, United States|USC Department of Dermatology, Los Angeles, California, 90033, United States|Thiele Dermatology Specialists, Inc, Murrieta, California, 92562, United States|Island Dermatology, Newport Beach, California, 92660, United States|Therapeutics Clinical Research, San Diego, California, 92123, United States|San Luis Dermatology and Laser Clinic, San Luis Obispo, California, 93405, United States|Southern California Dermatology, Inc., Santa Ana, California, 92701, United States|Olympian Clinical Research, Clearwater, Florida, 33756, United States|Spotlight Research Center, LLC, Miami, Florida, 33176, United States|Private Practice - Dr. Tory P. Sullivan, North Miami Beach, Florida, 33162, United States|Marietta Dermatology Clinical Research, Inc., Marietta, Georgia, 30060, United States|MedaPhase, Inc., Newnan, Georgia, 30263, United States|Northwestern University, Chicago, Illinois, 60611, United States|RUSH University, Chicago, Illinois, 60612, United States|Dawes-Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, 46256, United States|Kansas City Dermatology, PA, Overland Park, Kansas, 66215, United States|Beacon Clinical Research, Quincy, Massachusetts, 02169, United States|HFMC New Center One, Detroit, Michigan, 48202, United States|The Grekin Skin Institute, Warren, Michigan, 48088, United States|Respiratory Medicine Research Institute of Michigan, PLC, Ypsilanti, Michigan, 48197, United States|Clinical Studies Group, Henderson, Nevada, 89074, United States|Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, 08520, United States|Corning Center for Clinical Research, Corning, New York, 14830, United States|Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States|Sadick Dermatology, New York, New York, 10075, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States|University of Cincinnati Health Physicians Office, Cincinnati, Ohio, 45267, United States|Wright State Physicians, Fairborn, Ohio, 45324, United States|Aventiv Research Inc., Westerville, Ohio, 43082, United States|Oregon Dermatology and Research Center, Portland, Oregon, 97210, United States|Paddington Testing Company, Inc., Philadelphia, Pennsylvania, 19103, United States|Yardley Dermatology Associates, Yardley, Pennsylvania, 19067, United States|Clinical Research Center of the Carolinas, Charleston, South Carolina, 29407, United States|Rivergate Dermatology Clinical Research Center, Goodlettsville, Tennessee, 37072, United States|Bellaire Dermatology Associates, Bellaire, Texas, 77401, United States|Modern Research Associates, PLLC, Dallas, Texas, 75231, United States|Austin Institute for Clinical Research, Inc., Pflugerville, Texas, 78660, United States|Progressive Clinical Research, San Antonio, Texas, 78213, United States|Woden Dermatology Pty Ltd., Phillip, Australian Capital Territory, 2606, Australia|Skin & Cancer Foundation Australia, Darlinghurst, New South Wales, 2010, Australia|St. George Dermatology and Skin Cancer Center, Kogarah, New South Wales, 2217, Australia|Veracity Clinical Research, Woolloongabba, Queensland, 4102, Australia|Skin & Cancer Foundation Inc., Carlton, Victoria, 3053, Australia|Sinclair Dermatology, East Melbourne, Victoria, 3002, Australia|Burswood Dermatology, Victoria Park, Western Australia, 6100, Australia|Dr. Chih-ho Hong Medical, Surrey, British Columbia, V3R 6A7, Canada|Enverus Medical Research, Surrey, British Columbia, V3V 0C6, Canada|Pacific Derm, Vancouver, British Columbia, V6H 4E1, Canada|Winnipeg Clinic, Winnipeg, Manitoba, R3C 0N2, Canada|Wiseman Dermatology Research, Winnipeg, Manitoba, R3M 3Z4, Canada|Brunswick Dermatology Centre, Fredericton, New Brunswick, E3B 1G9, Canada|Nexus Clinical Research, St. John's, Newfoundland and Labrador, A1A 5E8, Canada|Eastern Canada Cutaneous Research, Halifax, Nova Scotia, B5H 1Z4, Canada|Kingsway Clinical Research, Etobicoke, Ontario, M8X 1Y9, Canada|Guenther Derm Research Centre, London, Ontario, N6A 3H7, Canada|Lynderm Research Inc., Markham, Ontario, L3P 1X2, Canada|DermEdge Research, Mississauga, Ontario, L5H 1G9, Canada|Dermatology & Cosmetic Surgery, North Bay, Ontario, P1B 3Z7, Canada|Derm Clinic of Dr. Robern, Ottawa, Ontario, K2G 6E2, Canada|Skin Centre for Dermatology, Peterborough, Ontario, K9J 5K2, Canada|Dermatology & Cosmetic Surgery, Richmond Hill, Ontario, L4B 1A5, Canada|K. Papp, Waterloo, Ontario, N2J 1C4, Canada|XLR8 Medical Research, Windsor, Ontario, N8W 1E6, Canada|Dr. David Gratton Dermatologue, Montréal, Quebec, H3H 1V4, Canada|CRDQ, Québec, Quebec, G1V 4X7, Canada|Aarhus University Hospital, Aarhus, Denmark|Bispebjerg Hospital, Hellerup, Denmark|Gentofte Hospital, Hellerup, Denmark|Spedali Civili Brescia, Brescia, 25123, Italy|Policlinico-Vittorio Emanuele, Catania, 95123, Italy|Opedale San Salvatore, L'Aquila, 67100, Italy|AOU Pisa, Pisa, 56126, Italy|IRCCS San Gallicano, Rom, 00144, Italy|Policlinico ""Agostino Gemelli"", Rom, 00168, Italy|Istituto Clinico Humanitas, Rozzano, 20089, Italy|Pusan National University Hospital, Busan, 49241, Korea, Republic of|Chungnam National Univeristy, Daejeon, 35015, Korea, Republic of|Chonnam National University Hospital, Gwangju, 61469, Korea, Republic of|Soon Chun Hyang University Hospital, Gyeonggi-do, 14584, Korea, Republic of|Korea University Ansan Hospital, Gyeonggi-do, 425-707, Korea, Republic of|St. Mary's Hospital, Incheon, 21431, Korea, Republic of|Inha University Hospital, Incheon, 22332, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Yonsei University Health Syste, Seoul, 03722, Korea, Republic of|Konkuk University Medical Center, Seoul, 05030, Korea, Republic of|Chung-Ang University Hospital, Seoul, 06973, Korea, Republic of|Hallym University Kangnam Sacr, Seoul, 07441, Korea, Republic of|Centrum Medyczne Gdynia, Gdynia, 81-338, Poland|Synexus Polska Gdyni, Gdynia, 81-384, Poland|Synexus Polska Katowicach, Katowice, 40-040, Poland|Centrum Medyczne PRATIA, Kraków, 30-002, Poland|Krakowskie Centrum Medyczne, Kraków, 31-501, Poland|Synexus Polska Poznaniu, Poznań, 60-702, Poland|Klinika Dermatologii, Rzeszów, 35-055, Poland|""DERMED"" Centrum Medyczne Sp., Łódź, 90-265, Poland|Dermoklinika Centrum Medyczne, Łódź, 90-436, Poland|Chelyabinsk Dermat. Dispensary, Chelyabinsk, 454048, Russian Federation|Federal State Budgetary Institution State Sci. Ctr., Moscow, 107076, Russian Federation|French clinic of skin diseases, Saint Petersburg, 191123, Russian Federation|Military Medical Academy, Saint Petersburg, 194044, Russian Federation|Ninewells Hospital, Dundee, Angus, DD2 1GZ, United Kingdom|Salford Royal Hospital, Salford, Greater Manchester, M6 8HD, United Kingdom|Whipps Cross University Hospital, Leytonstone, London, E11 1NR, United Kingdom|Harrogate District Hospital, Harrogate, North Yorkshire, HG2 7SX, United Kingdom|Royal Hallamshire Hospital, Sheffield, South Yorkshire, S10 2RX, United Kingdom|East Surrey Hospital, Redhill, Surrey, RH1 5RH, United Kingdom|Royal Victoria Infirmary, Newcastle upon Tyne, Tyne And Wear, NE1 4LP, United Kingdom|Russells Hall Hospital, Dudley, West Midlands, DY1 2HQ, United Kingdom|Walsall Healthcare NHS Trust, Walsall, West Midlands, WS2 9PS, United Kingdom|Chapel Allerton Hospital, Leeds, West Yorkshire, LS7 4SA, United Kingdom|West Suffolk Hospital, Bury St Edmunds, IP33 2QZ, United Kingdom|The Whittington Hospital NHS, London, N19 5NF, United Kingdom|Guy's Hospital, London, SE1 9RT, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/85/NCT03160885/Prot_001.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/85/NCT03160885/SAP_000.pdf"
